Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02. Following the transaction, the chief operating officer now owns 22,222 shares of the company’s stock, valued at $220,220.02. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ FENC traded down $0.13 during midday trading on Thursday, reaching $9.57. 159,643 shares of the stock were exchanged, compared to its average volume of 110,783. The stock has a 50 day moving average price of $10.10 and a 200-day moving average price of $9.33. Fennec Pharmaceuticals Inc has a 52-week low of $6.30 and a 52-week high of $11.92. The company has a market capitalization of $259.35 million, a P/E ratio of -15.69 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to analyst estimates of $9.47 million. On average, analysts forecast that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on FENC shares. HC Wainwright lifted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, April 4th. Craig Hallum lifted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price target on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Several hedge funds have recently modified their holdings of FENC. Royal Bank of Canada lifted its position in Fennec Pharmaceuticals by 21.1% during the fourth quarter. Royal Bank of Canada now owns 7,102 shares of the company’s stock valued at $79,000 after buying an additional 1,236 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after buying an additional 1,578 shares in the last quarter. Citigroup Inc. lifted its position in Fennec Pharmaceuticals by 10.3% during the first quarter. Citigroup Inc. now owns 18,590 shares of the company’s stock valued at $151,000 after buying an additional 1,742 shares in the last quarter. Vanguard Group Inc. lifted its position in Fennec Pharmaceuticals by 2.4% during the third quarter. Vanguard Group Inc. now owns 81,768 shares of the company’s stock valued at $614,000 after buying an additional 1,895 shares in the last quarter. Finally, Hartford Financial Management Inc. lifted its position in Fennec Pharmaceuticals by 4.4% during the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after buying an additional 2,000 shares in the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.